Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153675 | 0.94 | ADORA2A (0.39) | ADORA3ADORA2AADORA2BAXLFLT3 | |
| SCHEMBL4148652 | 0.90 | ADORA3 (0.39) | ADORA3ADORA2AADORA2BAXLFLT3 | |
| SCHEMBL4158667 | 0.90 | ADORA2A (0.47) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4161121 | 0.89 | AXL (0.36) | ADORA2AADORA2BP2RY12AXLFLT3 | |
| SCHEMBL4161125 | 0.89 | AXL (0.36) | ADORA2AADORA2BP2RY12AXLFLT3 | |
| SCHEMBL4161118 | 0.89 | AXL (0.36) | ADORA2AADORA2BP2RY12AXLFLT3 | |
| SCHEMBL4156164 | 0.86 | RXFP1 (0.43) | ADORA2AADORA2BP2RY12ADORA1 | |
| SCHEMBL4152301 | 0.83 | ADORA2A (0.55) | ADORA3ADORA2AADORA2B | |
| SCHEMBL14113287 | 0.81 | P2RY12 (0.54) | ADORA3ADORA2AADORA2BP2RY12 | |
| SCHEMBL4168665 | 0.78 | ADORA2A (0.65) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | ADORA3 29/4885ADORA2A 33/4885ADORA2B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.